Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.

Abstract

We compared for the first time the therapeutic potential of a specific phosphodiesterase 4 (PDE4) inhibitor, rolipram, with anti-VLA-4 and anti-IL-5 in a model of secondary allergen exposure of previously sensitized and challenged mice. To address these issues, mice were sensitized and challenged with ovalbumin (OVA) (primary challenge). Six weeks later… (More)

Topics

Cite this paper

@article{Kanehiro2001InhibitionOP, title={Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.}, author={Arihiko Kanehiro and Toshimichi Ikemura and Mikko M{\"a}kel{\"a} and Michael Lahn and Anthony Joetham and Azzedine Dakhama and E. W. Gelfand}, journal={American journal of respiratory and critical care medicine}, year={2001}, volume={163 1}, pages={173-84} }